Lupus & antiphospholipid syndrome
Belimumab induces early and sustained resolution of lupus thrombocytopenia
Authors' conclusion
This post hoc analysis of data from five large phase III RCTs suggests a benefit from belimumab compared with placebo in the haematological domain. A benefit from belimumab was seen in improving thrombocytopenia, but not leucopenia.
Study context
- Population
- Patients with SLE with active thrombocytopenia or leucopenia at baseline, from five phase III RCTs of belimumab
- Participants
- 1,769 vs 1,144
- Comparison
- Belimumab vs placebo, on top of standard therapy, in SLE with active thrombocytopenia or leucopenia at baseline
- Belimumabn = 1,769
- Placebon = 1,144reference
- Outcome
- Sustained resolution of thrombocytopenia or leucopenia from the time of resolution through week 52
- Follow-up
- Week 52
Methodological detailspooled data from five phase III RCTs, placebo-controlled, log-rank tests
- Pooled data from five phase III RCTs
- Placebo-controlled
- Log-rank tests
Pooled result
As reported in the abstract
Sustained resolution of thrombocytopenia
Belimumab
One-third
13 of 1769
Placebo
8%
2
P = 0.0267
Further pooled results
Resolution of leucopenia · week 52
- Improvements slower than in thrombocytopenia, with no apparent difference between belimumab and placebo (baseline leucopenia: 346 belimumab, 203 placebo)
Original publication
Belimumab induces early and sustained resolution of lupus thrombocytopenia. Lupus Sci Med. Published 17 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →